Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482061 | 0.81 | PLCG1 (0.52) | ATRPLCG1METAP1EGLN2SYK | |
| SCHEMBL30534254 | 0.81 | PLCG1 (0.52) | ATRPLCG1METAP1EGLN2SYK | |
| SCHEMBL4393718 | 0.81 | ATR (0.58) | ATRMETAP1CYP17A1AAK1NAMPT | |
| SCHEMBL5779641 | 0.78 | ATR (0.46) | ATRMETAP1CYP17A1AAK1NAMPT | |
| SCHEMBL3456534 | 0.71 | EGLN2 (0.47) | ATREGLN2CYP17A1AAK1 | |
| SCHEMBL5776893 | 0.71 | EGLN2 (0.38) | ATRMETAP1EGLN2CYP17A1AAK1 | |
| SCHEMBL4037373 | 0.71 | NAMPT (0.47) | ATRMETAP1CYP17A1NAMPT | |
| SCHEMBL30888170 | 0.71 | ATR (0.59) | ATRMETAP1CYP17A1AAK1NAMPT | |
| SCHEMBL16992920 | 0.71 | ATR (0.46) | ATRMETAP1CYP17A1AAK1NAMPT | |
| SCHEMBL1058106 | 0.70 | ATR (0.59) | ATRMETAP1CYP17A1AAK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | ATR 2336/4885PLCG1 1823/4885METAP1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.